Related Experiment Video
Updated: Dec 1, 2025
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
Medulloblastoma: "Onset of the molecular era"
Pavan Kumar Dhanyamraju1, Trupti N Patel2, Sinisa Dovat3
1Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA. pdhanyamraju@pennstatehealth.psu.edu.
Abstract:
Among brain tumors, Medulloblastoma (MB) is one of the most common, malignant, pediatric tumors of the cerebellum. It accounts for ~20% of all childhood central nervous system (CNS) tumors. Despite, tremendous advances in drug development processes, as well as novel drugs for MB the morbidity and mortality rates, remain high. Craniospinal radiation, high-dose chemotherapy, and surgical resection are the primary therapeutic strategies. Tremendous progress in the field of "genomics" with vast amounts of data has led to the identification of four distinct molecular subgroups in medulloblastoma: WNT group, SHH group, group-III, and group-IV. The identification of these subgroups has led to individualized treatment strategies for each subgroup. Here, we discuss the various molecular subgroups of medulloblastoma as well as the differences between them. We also highlight the latest treatment strategies available for medulloblastoma.
Insights
Medulloblastoma (MB), a common pediatric brain tumor, has high mortality despite advances. Genomic research identified four molecular subgroups (WNT, SHH, Group-III, Group-IV), enabling personalized treatment strategies for this challenging CNS tumor.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Genomics
Background:
- Medulloblastoma (MB) is a prevalent and malignant pediatric tumor originating in the cerebellum.
- It constitutes approximately 20% of all childhood central nervous system (CNS) tumors.
- Despite therapeutic advancements, MB continues to have high morbidity and mortality rates.
Purpose of the Study:
- To discuss the distinct molecular subgroups of medulloblastoma.
- To elucidate the differences among these identified subgroups.
- To highlight current and emerging treatment strategies tailored to each subgroup.
Main Methods:
- Genomic data analysis to classify medulloblastoma into distinct molecular subgroups.
- Review of current therapeutic approaches.
- Comparative analysis of subgroup characteristics and treatment responses.
Main Results:
- Identification of four primary molecular subgroups: WNT, SHH, Group-III, and Group-IV.
- These subgroups exhibit distinct biological and clinical characteristics.
- Genomic classification facilitates the development of individualized treatment plans.
Conclusions:
- Molecular subgrouping of medulloblastoma is crucial for understanding tumor heterogeneity.
- Personalized treatment strategies based on molecular subgroups offer improved therapeutic outcomes.
- Continued research into medulloblastoma genomics is vital for advancing pediatric CNS tumor treatment.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:21Cancers Originate from Somatic Mutations in a Single Cell
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...